key: cord-0755331-jyeht0pf
authors: Chow, Jonathan H.; Yin, Ying; Yamane, David P.; Davison, Danielle; Keneally, Ryan J.; Hawkins, Katrina; Parr, K. Gage; Al‐Mashat, Mustafa; Berger, Jeffery S.; Bushardt, Reamer L.; Mazzeffi, Michael A.; Nelson, Stuart J.
title: Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID‐19: A propensity score‐matched analysis
date: 2021-09-15
journal: J Thromb Haemost
DOI: 10.1111/jth.15517
sha: 3fcb04e9735e80b542952a463c8ca488e756487f
doc_id: 755331
cord_uid: jyeht0pf

PURPOSE: Coronavirus disease 2019 (COVID‐19) is associated with hypercoagulability and increased thrombotic risk. The impact of prehospital antiplatelet therapy on in‐hospital mortality is uncertain. METHODS: This was an observational cohort study of 34 675 patients ≥50 years old from 90 health systems in the United States. Patients were hospitalized with laboratory‐confirmed COVID‐19 between February 2020 and September 2020. For all patients, the propensity to receive prehospital antiplatelet therapy was calculated using demographics and comorbidities. Patients were matched based on propensity scores, and in‐hospital mortality was compared between the antiplatelet and non‐antiplatelet groups. RESULTS: The propensity score‐matched cohort of 17 347 patients comprised of 6781 and 10 566 patients in the antiplatelet and non‐antiplatelet therapy groups, respectively. In‐hospital mortality was significantly lower in patients receiving prehospital antiplatelet therapy (18.9% vs. 21.5%, p < .001), resulting in a 2.6% absolute reduction in mortality (HR: 0.81, 95% CI: 0.76–0.87, p < .005). On average, 39 patients needed to be treated to prevent one in‐hospital death. In the antiplatelet therapy group, there was a significantly lower rate of pulmonary embolism (2.2% vs. 3.0%, p = .002) and higher rate of epistaxis (0.9% vs. 0.4%, p < .001). There was no difference in the rate of other hemorrhagic or thrombotic complications. CONCLUSIONS: In the largest observational study to date of prehospital antiplatelet therapy in patients with COVID‐19, there was an association with significantly lower in‐hospital mortality. Randomized controlled trials in diverse patient populations with high rates of baseline comorbidities are needed to determine the ultimate utility of antiplatelet therapy in COVID‐19.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID- 19) , has infected more than 222 million people worldwide and has led to more than 4.6 million deaths globally. 1 Despite an unprecedented vaccination effort with more than 5.5 billion doses administered to date, novel SARS-CoV-2 variants with increased infectivity have accelerated the spread of the disease. New cases have been recorded at a rate of more than 412 000 infections per day in countries such as India, and new deaths have exceeded 12 400 patients per day worldwide. 2, 3 Numerous studies have found that COVID-19 is not only a respiratory disease that can cause acute respiratory distress syndrome, but also a disease characterized by endothelial cell dysfunction. 4 Patients with severe COVID-19 are now well known to have hypercoagulability and an increased risk for venous thromboembolism (VTE) and arterial thrombosis. [5] [6] [7] [8] VTEs in patients hospitalized with COVID- 19 have been reported at a rate ranging from 20% to 69%, with one study finding that VTEs were associated with a 2.4fold increase in the risk of death. [9] [10] [11] Therapeutic anticoagulation and intermediate-to high-dose deep vein thrombosis (DVT) prophylaxis have been used at many institutions, and small retrospective studies early in the pandemic found that these interventions were associated with improved outcomes. 12 Interim results from larger studies such as the Accelerating Covid-19 Therapeutic Interventions and Vaccines-4 Antithrombotics Inpatient trial found that although therapeutic anticoagulation decreased the need for mechanical ventilation in moderately ill patients, this benefit was not observed in critically ill patients. 13, 14 Because increased megakaryocytes have been observed in multiple organs on autopsy in COVID-19 patients, and because of the high rate of thromboembolic events, there may be a role for antiplatelet therapy in the treatment of this disease. [15] [16] [17] The first study of aspirin use in COVID-19 found that in 412 patients, aspirin was associated with a significantly decreased risk of mechanical ventilation, intensive care unit admission, and in-hospital mortality. 15 Another study of 638 propensity-matched patients found that aspirin was associated with a lower incidence of in-hospital mortality. 16 In a large propensity-matched study examining 12 600 predominately male patients in the Veterans Affairs (VA) health system, preadmission aspirin use was also associated with decreased 30-day mortality. 17 Given these data related to aspirin use in patients with COVID-19, our study objective was to explore the effect of prehospital antiplatelet therapy on mortality in hospitalized patients with COVID- 19 .

We hypothesized that antiplatelet therapy would be associated with a reduced risk of in-hospital mortality.

The COVID-19 Analysis to Assess the Mortality Impact of Antiplatelet Regimens at North American centers (CATAMARAN) study analyzed 34 675 COVID-19-positive patients from 90 health systems and 26 states in the United States. Patients were abstracted from the Cerner Network Real-World Dataset, which contains deidentified data of more than 89 million patients. 18 The dataset contains more than 17 million inpatient encounters, 161 million procedures, 6 million microbiology results, 903 million medications, and 11 billion laboratory results. These data concepts were cleansed, standardized, and deidentified with Health Insurance Portability and Accountability Act-compliant operating policies before publication in the Cerner Network Real-World data mart. 

Patient demographics, comorbidities, preadmission antiplatelet medication use, in-hospital therapeutics, and outcome data were collected for each patient. Antiplatelet use was defined as the use of aspirin, clopidogrel, dipyridamole, ticagrelor, or prasugrel before hospital admission. The study's primary outcome was in-hospital mortality. Based on previous studies, we hypothesized that antiplatelet therapy would be associated with decreased in-hospital mortality. For measures of risks and safety, we examined differences in the rate of hemorrhagic complications between the groups.

Hemorrhagic complications were identified with procedure codes for blood transfusion as well as with ICD-10 codes for cerebral hemorrhage, gastrointestinal bleeding, epistaxis, and pulmonary hemorrhage. In addition, we also analyzed differences in rates of thrombotic complications, such as ST-segment elevation myocardial infarction, pulmonary embolism (PE), acute DVT, arterial thrombosis, and thrombotic or embolic stroke.

To reduce bias, propensity score analysis was used with the Scikitlearn Python Library. 21 Specifically, for each patient, we created a propensity score for receiving prehospital antiplatelet therapy.

The independent variables in the propensity score model included age, gender, body mass index, race, chronic kidney disease, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, diabetes, prior stroke, and prior PE. Patients were then matched by propensity score in a one-to-two ratio using the nearest-neighbor approach with no replacement and a caliper size of 0.1. A matched dataset containing 17 347 patients was created. The standardized mean difference (SMD) for each covariate was calculated to evaluate the balance in baseline characteristics before and after matching. In addition, to further assess balance, the variance ratio of the continuous covariates in the antiplatelet and non-antiplatelet groups were calculated. 22 Variables with a SMD <0.1 and variance ratio <1 were considered to be well-balanced between the antiplatelet and nonantiplatelet groups. 22 The Mann-Whitney U test was used for nonparametric continuous variables such as admission vital signs, quick sequential organ failure assessment score, and laboratory values. The chi-square test was applied for categorical variables such as demographics and medical comorbidities. p values <.05 were considered statistically significant for all comparisons.

Differences in study outcomes between groups were tested for using the chi-square test. For the primary outcome, Kaplan-Meier estimates of cumulative survival were calculated along with the hazard ratio and 95% confidence interval. For in-hospital mortality, the number needed to treat (NNT) was calculated from the absolute risk reduction with antiplatelet therapy. Additional subgroup analysis exploring differences in outcomes in the aspirin, clopidogrel, and dual antiplatelet therapy groups were performed. Finally, a sensitivity analysis with calculation of an E-Value was performed to estimate the strength of an unadjusted confounding variable associated with both antiplatelet therapy and in-hospital mortality that would be needed to nullify the association between the two variables. 23 Our study was retrospective, and an a priori sample size calculation was not performed. However, post hoc calculations found that with the 17 347 patients in the matched cohort and with the observed in-hospital mortality rate of 21.5% in the non-antiplatelet therapy group, our sample size allowed for the detection of a 1.3% absolute mortality reduction and 5.8% relative mortality reduction,

given an alpha of 5% and 80% power. Statistical analysis was performed using Python 3 (Python Software Foundation).

The study included 34 675 patients from 90 health systems who were admitted with COVID-19. Median age was 69 years (interquartile range 60, 78) and 52.3% of patients were male (Table 1) Figure 3) . The E-value indicated that an unmeasured confounder would need to be associated with both prehospital antiplatelet therapy and in-hospital mortality at a minimum risk ratio of 1.77 (upper confidence limit 1.56). was only powered to detect a 3.5% to 3.9% absolute risk reduction in in-hospital mortality in these groups.

In a multicenter, retrospective, observational cohort study of 17 292

propensity-matched patients with COVID-19, prehospital antiplatelet therapy was associated with a significant decrease in in-hospital mortality and PE. In a disease that has devastated the global population, the observed 2.6% absolute risk reduction in mortality and number needed to treat of 39 could translate into a large number of patients who could benefit from antiplatelet therapy. Importantly, most patients in the antiplatelet therapy arm received aspirin, which is a widely available medication that is inexpensive and has a well described risk profile. which are critical pathways for platelet activation and aggregation. 28

Activation of COX-1 leads to the production of thromboxane A 2 and increased platelet reactivity. 28 Aspirin irreversibly inhibits platelet function by inhibiting COX-1. Similarly, the P2Y 12 receptor leads to activation of the glycoprotein IIb/IIIa receptor, which results in platelet degranulation, thromboxane A 2 production, and platelet aggregation. 29 Clopidogrel, ticagrelor, and prasugrel act on this pathway to antagonize the P2Y 12 receptor and decrease platelet aggregation. 29 COVID-19 leads to microthrombosis and is associated with megakaryocyte proliferation in the heart, lungs, and kidneys. 8, 30 In one study, one-third of postmortem patients had PE as the cause of death. 31 VTEs were also present in more than 50% of these patients, even though they were not suspected before death. 31 In .69 ). However, this study was limited by its relatively small size, and the results may be difficult to discern because of the inclusion of both patients who were chronically taking aspirin and patients who acutely received aspirin in the first 24 hours of admission. Although the CRUSH COVID study demonstrated a larger effect size for aspirin than the present study, it also included more critically ill patients.

Another study of 638 propensity-matched patients found that in-hospital aspirin use was associated with a lower incidence of in-hospital mortality (HR: 0.522; 95% CI, 0.336-0.812). 16 Even after accounting for the confounding effect of time inherent in the before-after study design, the sensitivity analysis demonstrated significantly lower in-hospital mortality in the aspirin group (HR: 0.036; 95% CI, 0.002-0.576). 16 Before our study, the largest investigation of aspirin in COVID-19

involved 12 600 propensity-matched patients from the VA health system. 17 The odds of 30-day mortality were significantly lower in patients with an active outpatient aspirin prescription (OR: 0.38; 95% CI, 0.33-0.45). 17 Mortality was reduced from 10.5% in the nonaspirin group to 4.3% in the aspirin group, which represented a 59.0% relative risk reduction in mortality. With its large sample size, this study further provides a strong rationale for the use of aspirin in COVID-19. However, as expected in many VA health system studies, the matched cohort comprised of 95.8% male veterans, and the results may not be generalizable to a more diverse patient population. 

The administration of antiplatelet drugs is not without complications and studies in non-COVID-19 populations have found an increased risk of bleeding in patients receiving aspirin for primary prevention of cardiovascular disease. 35, 36 Patients in the Aspirin in Reducing

Events in the Elderly randomized controlled trial were 1.38 times more likely to have a major hemorrhagic complication, and a systematic review found that patients were 1.43 times more likely to have a serious bleeding complication while on aspirin. 35, 36 We did not find that antiplatelet therapy resulted in an increase in blood transfusions during hospitalization. With the exception of epistaxis, we also did not find an increased risk of serious hemorrhagic complications such as cerebral, gastrointestinal, and pulmonary hemorrhage.

Although this is contrary to previous cardiovascular disease studies, it consistent with previous COVID-19 studies, possibly because COVID-19 is such a prothrombotic disease. These data suggest that although aspirin use may be associated with significant benefits in COVID-19, the bleeding risks should be carefully considered in each patient before therapy is initiated.

Although our study is strengthened by a diverse population of pa- Our study is also limited by the bias inherent in retrospective, observational studies. The matching process intrinsically results in the loss of some patients, which could affect the generalizability of our study's results. 37 The target matching ratio was 1:2, but not all patients in the treatment group could be matched with exactly two control patients, resulting in an actual matching ratio of 1:1.6. Although propensity score matching can account for observed biases, it cannot account for unmeasured confounders such as the quality of care provided to individual patients. 37 It is possible that unmeasured confounders could have introduced treatment bias to patients in our cohort. However, in our sensitivity analysis, the Evalue indicated that any confounding variable would have to have a minimum risk ratio of 1.77 to nullify the relationship between antiplatelet therapy and mortality that was observed in our study.

Finally, some patients in the control group received in-hospital antiplatelet therapy, and this may have led to an underestimation of the true effect size of prehospital antiplatelet therapy.

Finally, because each class of antiplatelet agent has a unique mechanism of action, it is plausible that they may influence mortality outcomes differently. Our subgroup analysis found significant mortality improvements in the aspirin versus the non-antiplatelet therapy groups. However, the differences in mortality between the clopidogrel versus non-antiplatelet groups and in the dual antiplatelet therapy versus non-antiplatelet therapy groups were not significant.

Similarly, head-to-head post hoc comparisons of each antiplatelet agent were performed to help guide future studies. No differences in mortality were found when comparing aspirin with clopidogrel and when comparing aspirin with dual antiplatelet therapy. However,

given the reduced sample size in both the clopidogrel and dual antiplatelet therapy cohorts, subgroup analyses involving these groups may have been underpowered to detect any differences. Future studies are necessary to determine if mortality outcomes are different for P2Y 12 antagonists, COX-1 inhibitors, or phosphodiesterase inhibitors. in an older, diverse patient population with relatively high rates of baseline cardiovascular comorbidities.

Dr. Chow has served on the Speaker's Bureau for La Jolla Pharmaceutical Company, outside the scope of the submitted work.

The other authors have no potential conflicts of interest to disclose.

Concept, design, analysis or interpretation of data: Jonathan H. 

The requirement for written informed consent was waived by the institutional review board.

Jonathan H. Chow https://orcid.org/0000-0003-1750-3416

World Health Organization Coronavirus disease (COVID-19) outbreak

New York Times Tracking coronavirus vaccinations around the world

Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches

COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure

Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Incidence of venous thromboembolism in hospitalized patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19

news-relea ses/fulldose-blood -thinn ers-decre ased-need-life-suppo rt-impro ved-outco me-hospi taliz ed-covid -19-patients

news-event s/news-relea ses/nih-activ -trial -blood -thinn erspause s-enrol lment -criti cally -ill-covid -19-patients

Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019

Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis

Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration

FAQ: COVID-19 de-identified data cohort access offer for academic researchers

Centers for Disease Control and Prevention. ICD-10-CM Official Guidelines for Coding and Reporting

Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations

Scikit-learn: machine learning in {P}ython

written on behalf of AMEB-DCTCG. Balance diagnostics after propensity score matching

Sensitivity analysis in observational research: introducing the E-value

Efficacy of tocilizumab in patients hospitalized with Covid-19

Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized With COVID-19 Pneumonia: a randomized clinical trial

Dexamethasone in hospitalized patients with Covid-19

Remdesivir for the treatment of Covid-19 -final report

Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy

P2Y12 platelet inhibition in clinical practice

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

Arterial thrombosis in coronavirus disease 2019 patients: a rapid systematic review

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv

Effect of aspirin on cardiovascular events and bleeding in the healthy elderly

Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis

Ten pearls and pitfalls of propensity scores in critical care research: a guide for clinicians and researchers